GGrantIndex
Sort

10,766 grants matching checkpoint inhibitor

Adoptive T Cell Therapy for Pancreatic Cancer

$613,867
Cassian Yee · University Of Tx Md Anderson Can Ctr · R01 · FY2022 · CA

Identification of pathways to mitigate Immune-Related Adverse Events with Cancer Immunotherapy

$613,843
Donald Ym Leung · National Jewish Health · U01 · FY2023 · AR

Development of First-in-Class RIPK1 Degraders to Improve Cancer Immunotherapies

$613,358
Jin Wang · Baylor College Of Medicine · R01 · FY2024 · CA

Adaptive Symptom Self-Management to Reduce Psychological Distress and Improve Symptom Management for Survivors on Immune Checkpoint Inhibitors

$613,316
Terry A Badger · University Of Arizona · R01 · FY2024 · CA

TOWARD TRANSLATION OF NANFORMULATED PACLITAXEL-PLATINUM COMBINATION

$613,059
Alexander V Kabanov · Univ Of North Carolina Chapel Hill · R01 · FY2021 · CA

Radiation and dendritic cells to hepatomas to improve immunotherapy response

$612,951
Sean S Park · Mayo Clinic Rochester · R01 · FY2024 · CA

Inhibiting Multi-Functional ALDOA for Cancer Therapy

$612,848
Garth Powis · Sanford Burnham Prebys Medical Discovery Institute · R01 · FY2019 · CA

Mechanism of spontaneous and DSB-induced repair

$612,421
Rodney J. Rothstein · Columbia University Health Sciences · R37 · FY2012 · GM

Cancer Immunotherapy Clinical Trials

$612,359
Julius Strauss · Division Of Basic Sciences - Nci · ZIA · FY2020 · CA

Dissecting a novel tumor-promoting axis in cholangiocarcinoma

$612,322
Daniela Sia · Icahn School Of Medicine At Mount Sinai · R01 · FY2025 · CA

Dissecting a novel tumor-promoting axis in cholangiocarcinoma

$612,322
Daniela Sia · Icahn School Of Medicine At Mount Sinai · R01 · FY2024 · CA

The Impact of Metastatic Site On Dendritic Cell-Driven Tumor Immunity

$612,272
David G Denardo · Washington University · U01 · FY2024 · CA

Molecular Pathways Regulating Tissue-resident Memory T cells in the Gut

$612,247
Michael Lawrence Dougan · Massachusetts General Hospital · R01 · FY2022 · AI

Evaluation of Novel Radiation Modifiers

$612,188
Deborah Citrin · Division Of Basic Sciences - Nci · ZIA · FY2010 · CA

Discovery of the next-generation RET-targeted drugs based on nicotinamide scaffold

$612,099
Jie Wu · University Of Oklahoma Hlth Sciences Ctr · R01 · FY2022 · CA

Radiation and dendritic cells to hepatomas to improve immunotherapy response

$612,054
Sean S Park · Mayo Clinic Rochester · R01 · FY2023 · CA

Mechanism of lysyl oxidase propeptide in oral squamous cell carcinoma microenvironments

$612,048
Philip C Trackman · Ada Forsyth Institute, Inc. · R56 · FY2024 · DE

Identification of small molecule inhibitors to exonuclease 1 for breast cancer treatment

$611,800
Binghui Shen · Beckman Research Institute/City Of Hope · U01 · FY2025 · CA

Systematic interrogation of the pancreatic cancer microenvironment in patient-derived specimens

$611,615
William C Hahn · Dana-Farber Cancer Inst · U01 · FY2020 · CA

MUC1-C Oncoprotein Evades Immune Destruction in Non-small Cell Lung Cancer

$611,442
Donald W. Kufe · Dana-Farber Cancer Inst · R01 · FY2019 · CA

Precision targeting of T cell cytotoxicity with PET

$611,272
Michael John Evans · University Of California, San Francisco · R01 · FY2024 · CA

Mechanism of spontaneous and DSB-induced repair

$611,183
Rodney J. Rothstein · Columbia University Health Sciences · R37 · FY2011 · GM

Microtubule Regulation

$611,119
Don W. Cleveland · Ludwig Institute For Cancer Res Ltd · R01 · FY2009 · GM

Identification of pathways to mitigate Immune-Related Adverse Events with Cancer Immunotherapy

$610,938
Donald Ym Leung · National Jewish Health · U01 · FY2022 · AR

Biomarkers for acute interstitial nephritis in humans

$610,901
Dennis G. Moledina · Yale University · R01 · FY2022 · DK